Akoya Biosciences Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-33.38	-16.52	-20.09	-20	-27.71	Upgrade
Depreciation & Amortization	2.17	2.08	1.82	1.56	1.27	Upgrade
Other Amortization	1.78	1.78	1.55	0.64	-	Upgrade
Asset Writedown & Restructuring Costs	19.45	-	-	-	-	Upgrade
Other Operating Activities	-	0.33	-	-	-0.03	Upgrade
Change in Accounts Receivable	0.62	-0.47	-0.25	-0.08	-0.05	Upgrade
Change in Other Net Operating Assets	-0.81	2.54	-1.21	-2.24	-1.78	Upgrade
Operating Cash Flow	-10.17	-10.27	-18.18	-20.11	-28.31	Upgrade
Capital Expenditures	-	-	-	-0.08	-0.57	Upgrade
Sale (Purchase) of Intangibles	-0.46	-24.37	-5.57	-8.51	-1.94	Upgrade
Other Investing Activities	-	-	-	-	0	Upgrade
Investing Cash Flow	-0.46	-24.37	-5.57	-8.59	-2.51	Upgrade
Long-Term Debt Issued	3.98	23.5	-	16.65	12.95	Upgrade
Long-Term Debt Repaid	-23.48	-5	-1.5	-11.15	-11.27	Upgrade
Net Debt Issued (Repaid)	-19.5	18.5	-1.5	5.5	1.68	Upgrade
Issuance of Common Stock	23.43	13.68	22.48	19.95	33.18	Upgrade
Other Financing Activities	6.6	-	-	-	-	Upgrade
Financing Cash Flow	10.53	32.18	20.98	25.46	34.86	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-	-0	Upgrade
Net Cash Flow	-0.1	-2.47	-2.78	-3.25	4.04	Upgrade
Free Cash Flow	-10.17	-10.27	-18.18	-20.19	-28.87	Upgrade
Free Cash Flow Margin	-2211.09%	-234.70%	-326.12%	-231.27%	-772.21%	Upgrade
Free Cash Flow Per Share	-0.01	-0.14	-10.26	-32.22	-69.89	Upgrade
Cash Interest Paid	0.26	1.01	4.3	2.43	2.88	Upgrade
Levered Free Cash Flow	-4.8	-30.72	-15.44	-27.75	-10.35	Upgrade
Unlevered Free Cash Flow	-4.63	-30.09	-12.76	-26.23	-8.62	Upgrade
Change in Working Capital	-0.19	2.07	-1.46	-2.31	-1.84	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.